2020年11月5日 · Background: Acute myeloid leukemias with KMT2A (formerly known as MLL-1) fusion genes (MLL-AML) and those with NPM1 mutations (NPM1-AML) are distinct subtypes as defined by the WHO classification.

In this review, we will discuss the normal biological roles of MLL1 and its fusion partners, how these roles are hypothesized to be dysregulated in the context of MLL1 rearrangements, and the clinical manifestations of this group of leukemias.

Direct induction of the MLL-AF9 fusion in various hematopoietic compartments in vivo using a doxycycline (DOX) regulated mouse model (iMLL-AF9) led to an invasive chemoresistant AML expressing several genes known to be involved in epithelial …

Akute myeloische Leukämien (AML) können de novo, nach einer vorausgegangenen zytotoxischen und/oder Strahlentherapie (AML-pCT), oder sekundär aus einer vorbestehenden myelodysplastischen/myeloproliferativen Erkrankung bzw. einem MDS entstehen.

We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a reciprocal translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK).

MLL gene rearrangements are well-recognized aberrations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In contrast, MLL gene amplification in AML/MDS remains poorly characterized. Here, we report a series of 21 patients with myeloid neoplasms associated with MLL gene amplificat …

The MLL gene, located at 11q23 band, is frequently disrupted by different chromosomal rearrangements that occur in a variety of hematological malignancies. MLL rearrangements are associated with distinct clinical features and a poor prognosis.

2011年11月13日 · AML with MLL gene alterations (11q23/ MLL+ AML) represents 3-4% of all AML cases and occurs most frequently in young people with “ de novo” AML (5-7%) and in treatment-induced AML (t-AML) patients (10-15%).

We have summarized the most important information on classification and diagnostic methods at MLL. In addition, we provide further links on prognosis and therapy in acute myeloid leukemia, so that you can inform yourself in more detail.

Objective: MLL gene is involved in more than 80 known genetic fusions in acute leukemia. To study the relevance of MLL partner gene and selected gene's expression, in this work, we have studied a cohort of 20 MLL-rearranged acute myeloid leukemia (AML).

2022年7月14日 · Acute myeloid leukemia with MLL amplification is associated with elderly patients, TP53 mutation, complex karyotype, frequent DIC, an aggressive clinical course, poor response to chemotherapy, and extremely short survival. Clinical trial approach is warranted.

MLL-fusion proteins can induce acute myeloid leukemias (AML) from either hematopoietic stem cells (HSC) or granulocyte macrophage progenitors (GMP), but it remains unclear if the cell of origin influences the biology of the resultant leukemia.

2018年9月12日 · Among major human acute myeloid leukemias (AMLs), MLL -rearranged AML (MLL -AML) is characteristic of poor prognosis due to refractoriness to chemotherapy and shorter period to relapse [1, 2,...

2020年9月1日 · Current treatments often fail to achieve a cure for AML patients in particular MLL-rearrangement AML. Emerging pre-clinical and clinical data show the promise of epigenetic therapies in AML. Many epigenetic factors also play important roles …

2025年2月3日 · Then, working collaboratively with researchers at Stanford, Meyerson’s research group studied a specific form of acute myeloid leukemia (AML) — one of the most difficult forms of leukemia to treat — which has mutations in KMT2A thatcreate an abnormal form of the MLL protein, that turns normal white blood cells into leukemia cells.

The MLL (mixed-lineage leukemia) gene, located on chromosome 11q23, is involved in chromosomal translocations in a subtype of acute leukemia, which represents approximately 10% of acute lymphoblastic leukemia and 2.8% of acute myeloid leukemia cases.

2025年3月1日 · Background Acute myeloid leukemia (AML) is a prevalent malignancy of the hematologic system. Despite advancements in therapeutic approaches, significant heterogeneity and therapeutic resistance pose substantial challenges to treatment. Tumors driven by core transcription factors through super-enhancers can establish core transcriptional regulatory …

To understand the molecular mechanism of leukemic relapse, MLL/AF9-transformed mouse leukemia cells were serially transplanted in C57BL/6 mice (N = 96) by mimicking repeated recurrences, where mutations were monitored by exome sequencing (N = 42).

At Moses Lake Industries (MLI), we develop and manufacture high-quality, leading-edge chemistries, while providing superior customer service and strengthening our team and communities for future generations. From semiconductors to energy storage, our R&D teams reimagine what’s possible.

Moses Lake Industries was established in 1984 as a wholly- owned subsidiary of Tama Chemicals. With an unparalleled commitment to customers and focus on innovation, we have grown to be a leading global supplier of high-performance chemical solutions to the semiconductor and flat panel industries.